HPV Serologic Testing

Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Dr. RM 1E144, Bethesda, MD 20892-9705, UNITED STATES. Description The National Cancer Institute (NCI) plans to procure on a sole source basis with Deutsches Krebsforschungszentrum (DKFZ) Im Neuenheimer Feld 280, D-69120 Heidelberg for HPV serologic testing. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as an Indefinite Delivery, Indefinite Quantity (IDIQ) type contract. The North American Industry Classification System code is 541380 and the business size standard is $14M. Period of performance is for twelve months from time of award plus one twelve month Option Year. It has been determined that there is no opportunity to acquire green products or services under this contract. Human papillomavirus (HPV) is the cause of cervical cancer, as well as subsets of cancers at other anatomic sites, including the oropharynx, vulva/vagina, penis, and anus. NCI recently reported that HPV16 E6 seropositivity was present in prediagnostic samples for 34.8% of oropharyngeal cancer cases and 0.6% of controls. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. NCI now aims to confirm our initial finding by testing additional samples from other studies, and to expand our research to anogenital cancers, in order to understand whether this potential cancer biomarker is unique to HPV-driven oropharyngeal cancer, or also predicts risk at other anatomic sites where HPV is known to be a causal factor. DKFZ is the only known lab that runs a Luminex-based serologic assay for the necessary HPV genotypes and proteins. In addition NCI is looking to confirm or refute previous findings on new samples from other cohort studies; thus it is imperative to use the same assay for the contingency of the experiment. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a quote or proposal, which will be considered by the government. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. Responses must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on September 10, 2013. Electronic responses will be accepted, an original and one copy must be sent to the NCI Office of Acquisitions at the address stated above or to contact@example.gov. All questions must be in writing and can be faxed (240) 276-5401or emailed to Erin Breedlove, Contract Specialist at contact@example.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-130142-EB on all correspondence.